Understanding NICE and SMC HTA Submissions: Key Determinants in UK's Drug Pricing and Reimbursement Landscape
Cost-effectiveness / cost-utility is the key determinant in the United Kingdom pricing & reimbursement landscape and costly drugs usually enter the market through various commercial arrangements. The cost-utility assessment hinges on the quality-adjusted-life-years (QALY) contributed by the medicine. A QALY, the product of life expectancy and a measure of the quality of the remaining years of life, considers the quantity and the quality of life generated by healthcare interventions.
- There are alternatives within the same therapeutic class that have previously been accepted for use, OR
- a low net budget impact is expected
Why Choose Justin Stindt Consultants for your pricing and reimbursement dossier in the UK?
Justin Stindt Consultants is an agency specialized in UK HTA dossiers for NICE, SMC and AWMSG. Our experienced team of consultants and experts will help you to articulate the cost-effectiveness of your product in the UK HTA dossiers.
Our company’s commitment lies in delivering HTA submissions that excel in written excellence, technical precision, and the art of weaving clear, captivating narratives. Our goal as a consulting agency is to ensure that each submission forms a cohesive, integrated, evidence-based story, moving away from a mere assortment of distinct clinical and health-economic elements typically found in an evidence package.
Our specialists hold a comprehensive understanding of the specific requirements outlined by NICE, the SMC, and AWMSG, which will help you enter the UK pharmaceutical market. Our firm partners with leading health economists to provide expertise and advice feeding into the model and dossier development.
Justin Stindt Consultants is your international agency with the right experts in supporting the preparation of NICE, AWMSG and SMC HTA submissions. Our services include (not limited to):
- Comprehensive project planning with clear timelines and milestones
- Strategic review of drug positioning
- Health Economic Modeling
- Dossier writing, both English originals and if required translations
- Dossier validation with Key Opinion Leaders, Health Economists and ex-members of NICE, AWMSG and SMC
- Submission process guidance and support
- Hearing preparation and support
- Strategic advice and participation in price negotiations
- Effective project management and communication throughout the process
At Justin Stindt Consultants, our team of experts has extensive experience in providing our firm’s clients with tailored support to provide access to patients in the UK as soon as possible at sustainable pricing and reimbursement conditions. If you are looking for a vendor to support your UK dossiers, select a service provider that will go the extra mile to enable HTA endorsement for your product.
Let Justin Stindt Consultants be your trusted global agency partner in unlocking pricing & reimbursement (P&R) opportunities for your product in the UK.
Contact us today to learn how we can tailor our services to meet your unique needs and make your pricing & reimbursement goals a reality.
Meet one of our Pricing and Reimbursement dossiers UK experts
Get in touch with our expert
CLIENT TESTIMONIALS
